Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Garrett L. Robinson"'
Autor:
Garrett L. Cornelison, Ileana Pedraza, Kendra Garrison, Elizabeth M. Kapeel, Channing Pletka, Abdul Khan, Jessica Momb, Rebecca Martin, Adam Bartos, Joseph D. Dekker, Jay Zhao, John Majercak, Garrett L. Robinson
Publikováno v:
Cancer Research. 83:P4-08
Engineered Toxin Bodies Specific for TROP2 Positive Cancers Authors: Garrett L. Cornelison, Ileana Pedraza, Kendra Garrison, Elizabeth M. Kapeel, Channing Pletka, Abdul Khan, Jessica Momb, Rebecca Martin, Adam Bartos, Joseph D. Dekker, Jay Zhao, John
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41848d10fe5100e4f2a8781c7f5b4dee
https://doi.org/10.1158/1538-7445.sabcs22-p4-08-18
https://doi.org/10.1158/1538-7445.sabcs22-p4-08-18
Autor:
Garrett L. Cornelison, Adam Bartos, Brigitte Brieschke, Jessica Momb, Ileana Pedraza, Elizabeth M. Kapeel, Rebecca Martin, Channing Pletka, Adrian Gonzalez, Joseph D. Dekker, Jay Zhao, John Majercak, Garrett L. Robinson
Publikováno v:
Cancer Research. 82:326-326
Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable of forced internali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5f2fe9c76ae838b6b9164c80a0f1ce5
https://doi.org/10.1158/1538-7445.am2022-326
https://doi.org/10.1158/1538-7445.am2022-326
Autor:
Swati Khanna, Elizabeth M. Kapeel, Lauren R. Byrne, Elizabeth Saputra, Steven Rivera, Lindsey Aschenbach, Lilia A. Rabia, Garrett L. Cornelison, Rachael M. Orlandella, Brigitte Brieschke, Michaela Sousares, Jay Zhao, Garrett L. Robinson, Chris Moore, Joseph D. Dekker
Publikováno v:
Cancer Research. 82:3543-3543
Targeting of PD-L1 checkpoint has shown clinical efficacy in multiple solid tumor indications. Currently approved PD-L1 targeted approaches rely on the blocking activity of monoclonal antibodies (mAbs) which sterically inhibit PD-L1 thus preventing P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c2dbc19c675d76e5455c7b7a21f5cb7
https://doi.org/10.1158/1538-7445.am2022-3543
https://doi.org/10.1158/1538-7445.am2022-3543
Autor:
Rachael M. Orlandella, Elizabeth M. Kapeel, Brigitte Brieschke, Garrett L. Robinson, Joseph D. Dekker, Chris B. Moore
Publikováno v:
Cancer Research. 82:2579-2579
Engineered Toxin Bodies (ETBs) represent a unique therapeutic strategy for fighting cancer by targeting and selectively destroying cancer cells or cancer-promoting immune cells. Featuring an antibody-based targeting domain fused with the cytotoxic, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d3fff8b659798cf01b12c7413b267c6
https://doi.org/10.1158/1538-7445.am2022-2579
https://doi.org/10.1158/1538-7445.am2022-2579
Autor:
Swati Khanna, Joseph D. Dekker, Betty Chang, Lilia A. Rabia, Garrett L. Robinson, Hilario J. Ramos, Garrett L. Cornelison, Elizabeth Saputra, Wenzhao Dong, Michaela Sousares, Jay Zhao, Lindsey Aschenbach
Publikováno v:
Cancer Research. 81:1628-1628
Targeting PD-L1 has shown clinical efficacy in multiple solid tumor indications. Currently approved PD-L1 targeted approaches rely on monoclonal antibodies which sterically inhibit PD-L1 and prevent PD-1 mediated checkpoint activity. While these mole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5c7c64bc122dc64e14639891733e046
https://doi.org/10.1158/1538-7445.am2021-1628
https://doi.org/10.1158/1538-7445.am2021-1628
Autor:
Garrett L. Robinson, Aimee Iberg, Melissa M. Singh, Joseph D. Dekker, Hilario J. Ramos, Jay Zhao, Sara LeMar, Erin Willert
Publikováno v:
Cancer Research. 80:521-521
CD45 is highly expressed on the cell surface of all nucleated hematopoietic cells, including malignant cells of B, T and myeloid lineage. CD45, a receptor tyrosine phosphatase that has important roles in antigen receptor signaling, has multiple isofo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a7bd4e6d818690a927193b29694d2ce
https://doi.org/10.1158/1538-7445.am2020-521
https://doi.org/10.1158/1538-7445.am2020-521
Autor:
Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Aimee Iberg, Asis K. Sarkar, Banmeet Anand, Brigitte Brieschke, Melissa M. Singh, Jack P. Higgins, Jay Zhao, Erin Willert
Publikováno v:
Cancer Research. 80:3366-3366
Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-route through intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97d1969a145eabf16102804111c31a3e
https://doi.org/10.1158/1538-7445.am2020-3366
https://doi.org/10.1158/1538-7445.am2020-3366
Autor:
Aimee Iberg, Joseph D. Dekker, Garrett L. Robinson, Edith Acquaye-Seedah, Erin Willert, Hilario J. Ramos, Lilia A. Rabia, Jay Zhao
Publikováno v:
Cancer Research. 80:2278-2278
Tumor resident regulatory T cells (Tregs) are important mediators of an immunosuppressive tumor microenvironment (TME) promoting tumor immune evasion. The presence of Tregs, and a higher ratio of Tregs to effector T cells in the TME, are associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4ac11ff4307e6c0ec0a603d5357a941
https://doi.org/10.1158/1538-7445.am2020-2278
https://doi.org/10.1158/1538-7445.am2020-2278
Autor:
Hilario J. Ramos, Erin Willert, Jay Zhao, Caleigh Howard, Garrett L. Cornelison, Garrett L. Robinson, Aimee Iberg
Publikováno v:
Cancer Research. 80:539-539
Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable of forcing internal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dac11b98460e0c4cd68c3f5bb7a65f4b
https://doi.org/10.1158/1538-7445.am2020-539
https://doi.org/10.1158/1538-7445.am2020-539
Autor:
Roger J. Waltzman, Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Brigitte Brieschke, Garrett L. Cornelison, Aimee T. Iberg, Asis K. Sarkar, Erin Willert, Jay Zhao
Publikováno v:
Journal of Clinical Oncology. 38:12-12
12 Background: Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b661295508d489a702c96aa893aa08e8
https://doi.org/10.1200/jco.2020.38.5_suppl.12
https://doi.org/10.1200/jco.2020.38.5_suppl.12